Sponsor	Phase
Pfizer	Phase 1
Radboud University	Phase 1
Oregon State University	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Superpharm	TOLBUTAMIDE	tolbutamide	TABLET;ORAL	088893-001	Nov 19, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	TOLBUTAMIDE	tolbutamide	TABLET;ORAL	089111-001	May 29, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	TOLBUTAMIDE	tolbutamide	TABLET;ORAL	086574-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 1, 2026

Tolbutamide is a mature, low-value generic sulfonylurea with no meaningful remaining U.S. patent or regulatory exclusivity. Its commercial base has contracted as metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors displaced first-generation sulfonylureas. Current value is concentrated in low-cost generic supply, legacy prescriptions, and limited international markets. Public data do not provide a reliable standalone revenue series for tolbutamide.

Tolbutamide Market Dynamics, Patent Status, and Financial Trajectory

What is tolbutamide and how is it used?

Tolbutamide is a first-generation sulfonylurea used to treat type 2 diabetes. It stimulates pancreatic beta cells to release insulin and requires residual endogenous insulin production. It is administered orally, commonly in 500 mg tablets, with dosing divided across the day.

The drug was marketed in the United States under the brand name Orinase. Its FDA approval dates to the early era of oral diabetes therapy, before the modern generic-drug and Hatch-Waxman framework became commercially important.[1]

Tolbutamide has a shorter duration of action than several later sulfonylureas, including glyburide and glimepiride. Its principal clinical risk is hypoglycemia. Other concerns include weight gain, reduced suitability in older patients, and diminished use in patients with renal or hepatic impairment.

Attribute	Tolbutamide
Drug class	First-generation sulfonylurea
Active ingredient	Tolbutamide
Primary indication	Type 2 diabetes
Route	Oral
Common strength	500 mg tablet
Original brand	Orinase
Mechanism	Insulin secretagogue
FDA approval era	1950s
Current commercial status	Generic, mature, limited market
Biosimilar exposure	None
U.S. patent protection	No commercially relevant active estate identified
Main competitive pressure	Newer diabetes therapies and other generics

What is the FDA regulatory status of tolbutamide?

Tolbutamide remains an established small-molecule drug, but its U.S. regulatory position is materially different from that of a newly approved branded product.

The FDA has historically approved tolbutamide tablets through legacy applications and generic abbreviated new drug applications. The original branded product is no longer a meaningful commercial franchise. Current product availability depends on individual manufacturers and distributors rather than on a single originator company.

Tolbutamide does not have biologic status, so biosimilar regulation under the Public Health Service Act is irrelevant. Generic manufacturers compete through the abbreviated new drug application pathway under the Federal Food, Drug, and Cosmetic Act.

The FDA labeling history includes warnings concerning cardiovascular mortality and other risks associated with sulfonylurea therapy. Those warnings have reduced the attractiveness of first-generation sulfonylureas relative to newer agents and helped shift prescribing toward treatments with broader outcome data.[2]

What is the Orange Book status of tolbutamide?

Tolbutamide has no commercially significant Orange Book patent or regulatory exclusivity position comparable to a recently approved branded drug. The relevant product and application history is legacy-based, and any remaining U.S. market access depends primarily on generic approvals and manufacturing economics rather than patent barriers.[3]

The Orange Book is not a complete inventory of every historical right associated with a drug. It lists patents submitted by NDA holders for approved products and provides information on therapeutic equivalence. For tolbutamide, the practical commercial conclusion is clear: patent-listed exclusivity does not control market entry.

What patents protect tolbutamide?

No meaningful live U.S. composition-of-matter patent protects tolbutamide. Any original compound patent rights expired many decades ago.

Tolbutamide was commercialized before the modern wave of pharmaceutical lifecycle management. Its basic chemical structure, oral tablet form, and principal method of treating type 2 diabetes are old technologies. The relevant patent categories are:

Patent category	Commercial relevance
Composition of matter	Expired
Basic oral tablet	Expired or commercially irrelevant
Treatment of type 2 diabetes	Expired or not capable of blocking ordinary generic use
Salt or polymorph rights	No material blocking estate identified
Controlled-release formulation	No widely recognized active U.S. barrier
Manufacturing process	No public evidence of a market-blocking process estate
Device or delivery system	Not relevant to the conventional product

What formulations are protected by tolbutamide patents?

The principal commercial product is an immediate-release oral tablet. There is no high-value formulation franchise comparable to controlled-release products such as extended-release metformin or modified-release branded therapies.

Any historical formulation patents would have expired or lost practical value. A generic manufacturer can generally compete with a conventional tolbutamide tablet without licensing an originator formulation technology.

When did tolbutamide lose exclusivity?

Tolbutamide lost practical market exclusivity long before the current pharmaceutical patent environment. Its original U.S. approval occurred in the 1950s, and any regulatory exclusivity associated with that approval has long expired.

Event	Approximate timing	Commercial effect
Original U.S. approval	1950s	Established the Orinase franchise
Original patent and market protection	Mid-20th century	Expired decades ago
Generic competition	Late 20th century	Removed branded pricing power
Modern diabetes displacement	1990s onward	Reduced clinical demand
Current market	2020s	Low-price, fragmented generic supply

There is no credible basis for projecting a future patent cliff for tolbutamide. The relevant commercial decline already occurred through historical genericization and therapeutic substitution.

Are there Paragraph IV challenges to tolbutamide?

Paragraph IV litigation is not a meaningful current issue for tolbutamide. Paragraph IV certifications challenge listed patents for an approved reference drug. Because tolbutamide has no commercially relevant active patent estate, a new Paragraph IV event would have little strategic importance.

No publicly significant recent Paragraph IV dispute involving tolbutamide has shaped the U.S. market. Generic entry is not constrained by an active originator patent settlement or a 30-month stay.

What patent litigation affects tolbutamide?

No major active U.S. patent litigation involving tolbutamide is publicly identified as a current market driver. Historical disputes, if any, would have no material effect on present pricing or supply because the drug’s market is already genericized.

This distinguishes tolbutamide from high-revenue branded products where patent litigation determines launch timing, settlement economics, and the value of authorized generics.

How strong is the patent estate for tolbutamide?

The patent estate is commercially weak and effectively non-blocking.

A practical scoring framework is:

Factor	Assessment
Composition patent	None active
Core method-of-use protection	None active
Formulation protection	Limited to none
Manufacturing protection	No material barrier identified
Orange Book leverage	Low
Litigation leverage	Low
Generic entry risk	Very high
Lifecycle-management value	Minimal

Tolbutamide has no remaining intellectual-property feature that can support premium pricing or prevent substitution. A manufacturer’s competitive position depends on product quality, supply reliability, manufacturing cost, distribution, and regulatory compliance.

Which companies are challenging or competing with tolbutamide?

Tolbutamide competes primarily with other low-cost diabetes medicines rather than with a defined group of branded challengers.

Direct generic competitors

Potential direct competitors include manufacturers of tolbutamide tablets and distributors sourcing from contract manufacturers. The U.S. product field can change as companies discontinue, reintroduce, or transfer generic applications. Product availability therefore requires review of current FDA listings, National Drug Code records, wholesaler catalogs, and manufacturer supply notices.

Therapeutic competitors

The larger competitive set includes:

Metformin
Glipizide
Glyburide
Glimepiride
Pioglitazone
DPP-4 inhibitors
GLP-1 receptor agonists
SGLT2 inhibitors
Insulin

Metformin has become the standard low-cost initial therapy for many patients. Glipizide and glimepiride generally have stronger contemporary prescribing positions among sulfonylureas. GLP-1 receptor agonists and SGLT2 inhibitors have expanded because of cardiovascular, renal, and weight-related benefits that tolbutamide does not provide.

How does tolbutamide compare with newer diabetes drugs?

Tolbutamide has a low acquisition cost but limited clinical differentiation.

Factor	Tolbutamide	Metformin	GLP-1 receptor agonists	SGLT2 inhibitors
Generic availability	Yes	Yes	Limited or product-specific	Increasing
Hypoglycemia risk	Meaningful	Low when used alone	Low	Low
Weight effect	Gain	Neutral or modest loss	Loss	Modest loss
Cardiovascular outcome positioning	Weak	Established first-line role	Strong for selected products	Strong for selected products
Renal outcome positioning	Limited	Dose restrictions apply	Product-specific	Strong for selected products
Pricing power	Minimal	Minimal	High for branded products	High for branded products
Patent value	None	Mostly expired	Product-specific	Product-specific

Tolbutamide can remain relevant where cost is the dominant consideration and alternative medicines are unavailable. It is poorly positioned in formularies that prioritize hypoglycemia reduction, weight management, cardiovascular protection, or kidney outcomes.

What is the financial trajectory for tolbutamide?

Tolbutamide’s financial trajectory is structurally declining or flat at a very low base.

There is no widely reported standalone revenue stream for tolbutamide in the public filings of major pharmaceutical companies. The product is generally too small to receive separate revenue disclosure. Sales are likely recorded within broader generic portfolios, diabetes products, or regional pharmaceutical segments.

Revenue drivers

The remaining revenue pool is determined by:

Unit demand from legacy prescribing.
Availability of approved manufacturers.
Generic tablet pricing.
Hospital and pharmacy procurement.
International demand in markets with lower access to newer diabetes therapies.

Revenue constraints

The principal constraints are:

Therapeutic substitution by metformin and newer agents.
Low per-tablet pricing.
Lack of brand loyalty.
No patent-based price protection.
Limited promotional investment.
Potential manufacturing discontinuations.
Clinical concern over hypoglycemia and older sulfonylurea warnings.

For a generic manufacturer, tolbutamide can generate incremental portfolio revenue if production uses existing tablet capacity and the product has stable demand. It is unlikely to justify dedicated commercial infrastructure, major clinical investment, or a branded relaunch.

What generic launch scenarios exist for tolbutamide?

Generic entry is already established. The relevant scenarios are supply expansion, supply contraction, and opportunistic regional entry rather than a conventional first generic launch.

Scenario	Likely outcome
New low-cost manufacturer enters	Price pressure increases; supply improves
Existing manufacturer exits	Shortages or regional price increases may occur
Product is reintroduced after discontinuation	Limited demand may return through institutional channels
Branded relaunch	Unlikely to achieve durable premium pricing
New formulation launch	Commercially unattractive without clinical differentiation
International expansion	Possible in price-sensitive markets, but limited by local registration and demand

The highest commercial risk is supply fragility. When few manufacturers remain, a small product can experience shortages even though demand is weak. That creates temporary pricing opportunities but does not establish durable market power.

What manufacturing and intellectual-property barriers affect tolbutamide?

Manufacturing barriers are operational rather than proprietary. Tolbutamide is a conventional small-molecule tablet with no complex delivery system, biologic production process, or specialized device requirement.

A prospective manufacturer would face:

API sourcing and qualification
Tablet manufacturing validation
Stability testing
Dissolution and bioequivalence requirements
cGMP compliance
FDA facility inspection
Supply-chain continuity
Packaging and labeling compliance

The absence of active composition or formulation patents simplifies entry. Manufacturing economics remain difficult because low prices limit the return on regulatory and quality investments.

Is tolbutamide a licensing opportunity?

Tolbutamide has limited licensing value. An acquisition or license could make sense only as part of a broader generic portfolio, a regional supply arrangement, or a contract-manufacturing strategy.

A standalone license would have weak economics because:

No exclusivity can be transferred.
No proprietary formulation is evident.
No active patent royalty stream exists.
Clinical differentiation is limited.
Prescriber demand is narrow.
Regulatory maintenance costs can exceed product-specific profit.

The most plausible transaction is an asset transfer involving an abbreviated new drug application, manufacturing rights, or a regional marketing authorization rather than an innovation license.

What is the outlook for tolbutamide through 2030?

Tolbutamide is likely to remain a niche generic product through 2030. Its volume may persist in selected markets, formularies, and legacy treatment settings, but its share of diabetes spending should continue to decline.

The product has no expected patent cliff, no biosimilar wave, and no high-value regulatory event. Financial performance will depend on the number of active suppliers and the ability to maintain economical production. Any revenue growth would most likely reflect temporary supply disruption, geographic expansion, or portfolio consolidation rather than increased clinical adoption.

Key Takeaways

Tolbutamide is a first-generation generic sulfonylurea with no meaningful remaining U.S. patent exclusivity.
Its original Orinase franchise has been replaced by low-price generic supply.
No material Paragraph IV litigation, patent settlement, or active Orange Book barrier drives the market.
The main threat is therapeutic substitution by metformin, glimepiride, GLP-1 receptor agonists, SGLT2 inhibitors, and other modern therapies.
Public companies generally do not report tolbutamide revenue separately.
Commercial value is limited to low-cost manufacturing, regional supply, and portfolio economics.
The most important market variable is supplier continuity, not intellectual property.
Through 2030, tolbutamide is likely to remain available in selected markets but continue to lose clinical and financial relevance.

FAQs

Does tolbutamide still have a branded product in the United States?

Orinase is not a meaningful active branded franchise in the U.S. Current access, where available, is primarily through generic products and regional suppliers.

Can a company obtain orphan-drug exclusivity for tolbutamide?

Tolbutamide is an established treatment for type 2 diabetes and is not positioned as an orphan drug. Orphan designation would not ordinarily provide a commercial pathway for the conventional indication.

Is tolbutamide interchangeable with glipizide?

The drugs are both sulfonylureas, but they are not automatically interchangeable at the same dose. Therapeutic substitution requires prescriber assessment of dose, duration, hypoglycemia risk, renal function, and patient response.

Does tolbutamide have extended-release patent protection?

No commercially important active extended-release patent estate is associated with conventional tolbutamide treatment. Any historical formulation rights would not be expected to block ordinary generic tablet competition.

Could tolbutamide shortages increase its price?

Yes. A small number of active manufacturers can create supply-driven price increases or temporary shortages. Such pricing would reflect constrained supply rather than patent protection or durable brand power.

References

U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Tolbutamide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
American Diabetes Association Professional Practice Committee. (2024). Standards of care in diabetes, 2024. Diabetes Care, 47(Supplement_1). https://diabetesjournals.org/care/issue/47/Supplement_1
U.S. Food and Drug Administration. (n.d.). Electronic Orange Book patent and exclusivity information. https://www.accessdata.fda.gov/scripts/cder/ob/

US Patents:	0
Tradenames:	3
Applicants:	14
NDAs:	18
Raw Ingredient (Bulk) Api Vendors:	95
Clinical Trials:	30
Patent Applications:	7,252
What excipients (inactive ingredients) are in tolbutamide?	tolbutamide excipients list
DailyMed Link:	tolbutamide at DailyMed

Tolbutamide - Generic Drug Details

What are the generic drug sources for tolbutamide and what is the scope of patent protection?

Summary for tolbutamide

Recent Clinical Trials for tolbutamide

Medical Subject Heading (MeSH) Categories for tolbutamide

Anatomical Therapeutic Chemical (ATC) Classes for tolbutamide

US Patents and Regulatory Information for tolbutamide